{"id":674,"date":"2015-08-30T17:15:32","date_gmt":"2015-08-30T15:15:32","guid":{"rendered":"http:\/\/swedenbio.se\/?post_type=medlemmar&#038;p=674"},"modified":"2021-03-03T10:44:31","modified_gmt":"2021-03-03T09:44:31","slug":"orexo-ab","status":"publish","type":"medlemmar","link":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/","title":{"rendered":"Orexo"},"content":{"rendered":"<p><span class=\"Apple-style-span\">The company is commercializing its proprietary product, Zubsolv\u00ae sublingual tablets, for treatment of opioid dependence, in the US. The Zubsolv sublingual tablet is an advanced formulation of buprenorphine and naloxone using Orexo\u2019s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The company is commercializing its proprietary product, Zubsolv\u00ae sublingual tablets, for treatment of opioid dependence, in the US. The Zubsolv sublingual tablet is an advanced formulation of buprenorphine and naloxone using Orexo\u2019s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"user_categories":[44,6],"class_list":["post-674","medlemmar","type-medlemmar","status-publish","hentry","user_categories-life-science-companies","user_categories-pharma"],"acf":[],"aioseo_notices":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orexo - SwedenBIO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orexo - SwedenBIO\" \/>\n<meta property=\"og:description\" content=\"The company is commercializing its proprietary product, Zubsolv\u00ae sublingual tablets, for treatment of opioid dependence, in the US. The Zubsolv sublingual tablet is an advanced formulation of buprenorphine and naloxone using Orexo\u2019s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/\" \/>\n<meta property=\"og:site_name\" content=\"SwedenBIO\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-03T09:44:31+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/orexo-ab\\\/\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/orexo-ab\\\/\",\"name\":\"Orexo - SwedenBIO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#website\"},\"datePublished\":\"2015-08-30T15:15:32+00:00\",\"dateModified\":\"2021-03-03T09:44:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/orexo-ab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/orexo-ab\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/medlemmar\\\/orexo-ab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orexo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/\",\"name\":\"SwedenBIO\",\"description\":\"Branschorganisationen f\u00f6r svenska life science f\u00f6retag\",\"publisher\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#organization\",\"name\":\"SwedenBIO\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/swedenbio.se\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/swedenbio.se\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/logo.png\",\"width\":240,\"height\":59,\"caption\":\"SwedenBIO\"},\"image\":{\"@id\":\"https:\\\/\\\/swedenbio.se\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orexo - SwedenBIO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/","og_locale":"en_US","og_type":"article","og_title":"Orexo - SwedenBIO","og_description":"The company is commercializing its proprietary product, Zubsolv\u00ae sublingual tablets, for treatment of opioid dependence, in the US. The Zubsolv sublingual tablet is an advanced formulation of buprenorphine and naloxone using Orexo\u2019s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, [&hellip;]","og_url":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/","og_site_name":"SwedenBIO","article_modified_time":"2021-03-03T09:44:31+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/","url":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/","name":"Orexo - SwedenBIO","isPartOf":{"@id":"https:\/\/swedenbio.se\/en\/#website"},"datePublished":"2015-08-30T15:15:32+00:00","dateModified":"2021-03-03T09:44:31+00:00","breadcrumb":{"@id":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/swedenbio.se\/en\/medlemmar\/orexo-ab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/swedenbio.se\/en\/"},{"@type":"ListItem","position":2,"name":"Orexo"}]},{"@type":"WebSite","@id":"https:\/\/swedenbio.se\/en\/#website","url":"https:\/\/swedenbio.se\/en\/","name":"SwedenBIO","description":"Branschorganisationen f\u00f6r svenska life science f\u00f6retag","publisher":{"@id":"https:\/\/swedenbio.se\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/swedenbio.se\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/swedenbio.se\/en\/#organization","name":"SwedenBIO","url":"https:\/\/swedenbio.se\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/swedenbio.se\/en\/#\/schema\/logo\/image\/","url":"https:\/\/swedenbio.se\/wp-content\/uploads\/2020\/09\/logo.png","contentUrl":"https:\/\/swedenbio.se\/wp-content\/uploads\/2020\/09\/logo.png","width":240,"height":59,"caption":"SwedenBIO"},"image":{"@id":"https:\/\/swedenbio.se\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar\/674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar"}],"about":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/types\/medlemmar"}],"author":[{"embeddable":true,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/comments?post=674"}],"version-history":[{"count":2,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar\/674\/revisions"}],"predecessor-version":[{"id":23803,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/medlemmar\/674\/revisions\/23803"}],"wp:attachment":[{"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/media?parent=674"}],"wp:term":[{"taxonomy":"user_categories","embeddable":true,"href":"https:\/\/swedenbio.se\/en\/wp-json\/wp\/v2\/user_categories?post=674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}